Editorial: Neuromodulation technology: advances in optics and acoustics
Meijun Ye,Chen Yang,Ji-Xin Cheng,Hyeon Jeong Lee,Ying Jiang,Linli Shi
DOI: https://doi.org/10.3389/fncel.2024.1494457
2024-10-09
Frontiers in Cellular Neuroscience
Abstract:It is estimated that about 43.3 million people are blind and 295 million with moderate to severe visual impairment worldwide in 2020 [1]. Retinal prostheses, a type of implantable electronic device, are designed to deliver electrical current to the retina to activate residual neurons for partial restoration of light perception in blind patients. Early generations of retinal prostheses involved implanting an electrode array on or under the retina, namely epiretinal and subretinal prostheses. These prostheses have limitations of low spatial resolution, off-target stimulation, low reliability, and mechanical and material stress to the retina. Nanoparticles (NP) that can transduce optical, acoustic, or magnetic fields into neural electrical responses have the potential to overcome these limitations and serve as next-generation retinal prostheses with the advantages of being less invasive and cell-type specific.Stoddart, Paul R., et al. summarized NP transducers that can be activated by light for retinal neuromodulation in their review article [2]. By conjugating NPs with versatile materials or ligands, retinal cells can be stimulated by light through different mechanisms, such as photothermal, photomechanical, photoacoustic, photovoltaic, and photochemical effects. Echoing this review, Rahmani A and Eom K reported an enhanced organic photovoltaic-based retinal prosthesis utilizing plasmonic NP to improve light-to-electricity conversion [3]. This technology can significantly increase the efficiency of such devices while minimizing the physical footprint and energy requirements for patients with retinal degenerative diseases. Their computational analysis shows a 10% increase in current density for the photovoltaic cell with the developed structure containing K-AgNPs. Additionally, the simulation results indicate that the modeled device doubles the efficiency of a bare photovoltaic cell. As reviewed by Stoddart, Paul R., et al., these optical innovations offer promising tools that extend beyond traditional methods, providing new opportunities to restore visual functions.While NP-based retinal prostheses are still under investigation, optogenetics, which allows for precise control over neural activity through genetically encoded light-sensitive proteins, has shown effectiveness in partially restoring visual perception in retinitis pigmentosa patients [4]. The application of optogenetics in other neurological conditions is also under active exploration. One example is the research conducted by Kc, Elina, et al., which involved expressing Channelrhodopsin and Halorhodopsin in the trigeminal ganglion of a trigeminal neuralgia rat model [5]. They found that inhibition of trigeminal ganglion through Halorhodopsin activation, rather than Channelrhodopsin, significantly reduced pain-related behavioral and electrophysiological signatures. These results suggest that optogenetics can effectively manage the pain in trigeminal neuralgia, offering a non-pharmacological alternative for chronic pain management.Beyond its therapeutic potential in correcting abnormal neural activity in various neurological disorders, the specificity and reversibility of optogenetic modulation make it an invaluable tool for studying physiological and pathological neural circuits. In the research by Xiang, Xuaner, et al., optogenetics was used to investigate the role of the orexinergic system in anesthesia arousal and pain modulation [6]. Utilizing retrograde and anterograde labeling techniques, Xiang and colleagues delineated the pathways through which orexinergic neurons influence key brain regions involved in arousal. Furthermore, by optogenetically activating Channelrhodopsin expressing orexin neurons in the hypothalamus, robust arousal was elicited from light isoflurane anesthesia in mice. This insight opens new avenues for targeted interventions in anesthesia and analgesia, potentially leading to more effective and patient-specific treatment strategies. This synergistic integration of optogenetics with orexinergic research not only enhances our grasp of brain function but also paves the way for innovative therapeutic applications that could significantly improve the management of arousal and pain in clinical settings.Building on the principles of optogenetics while incorporating the non-invasive advantages of ultrasound, sonogenetics is emerging as a new neuromodulation approach that harnesses ultrasound to manipulate genetically modified cells. The review article by Wang, Hsien-Chu, et al. presents a comprehensive overview of ultrasound-responsive mediators, explores the molecular mechanisms underlying their response to ultrasound stimulation, and summarizes their applications in neuromodulation [7]. The genetic tools are employed to facilitate the targeted expression of ultrasound-sensing proteins in specific cell types, thereby enhancing their sensitivity to ultrasound compared to unmodified -Abstract Truncated-
neurosciences